Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer

Cancer Research

Volumn 71, Issue 10, 2011, Pages 3720-3731

  Cerliani, Juan P ^a   Guillardoy, Tomás ^a   Giulianelli, Sebastián ^a   Vaque, José P ^d   Gutkind, J Silvio ^d   Vanzulli, Silvia I ^b   Martins, Rubén ^c   Zeitlin, Eduardo ^c   Lamb, Caroline A ^a   Lanari, Claudia ^a  

^a Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^b ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^c Bancario Clinic   (Argentina)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; ANTIGESTAGEN; CYCLIN D1; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MEDROXYPROGESTERONE ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; STAT5 PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER RISK; CANCER TISSUE; CANCER TRANSPLANTATION; CELL NUCLEUS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; ENZYME ACTIVATION; FEMALE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM; REPORTER GENE; SCID MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDROXYPROGESTERONE ACETATE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTORS, PROGESTERONE; STAT5 TRANSCRIPTION FACTOR;

EID: 79956070963     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3074     Document Type: Article

References (50)

1. Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocr Rev 1990;11:221-65. (Pubitemid 20182870)
2. Lanari C, Lamb CA, Fabris VT, Helguero LA, Soldati R, Bottino MC, et al. The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 2009;16:333-50.
3. Giulianelli S, Cerliani JP, Lamb CA, Fabris VT, Bottino MC, Gorostiaga MA, et al. Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: a role for the FGF-2/FGFR-2 axis. Int J Cancer 2008;123:2518-31.
4. Cerliani JP, Giulianelli S, Sahores A, Wargon V, Gongora A, Baldi A, et al. Mifepristone inhibits MPA-and FGF2-induced mammary tumor growth but not FGF2-induced mammary hyperplasia. Medicina (B Aires) 2010;70:529-32.
5. Jackson D, Bresnick J, Rosewell I, Crafton T, Poulsom R, Stamp G, et al. Fibroblast growth factor receptor signalling has a role in lobuloalveolar development of the mammary gland. J Cell Sci 1997;110:1261-8. (Pubitemid 27273696)
6. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-4. (Pubitemid 47014500)
7. Meyer KB, Maia AT, O'Reilly M, Teschendorff AE, Chin SF, Caldas C, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 2008;6:e108.
8. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-49. (Pubitemid 40616112)
9. Yang X, Qiao D, Meyer K, Friedl A. Signal transducers and activators of transcription mediate fibroblast growth factor-induced vascular endothelial morphogenesis. Cancer Res 2009;69:1668-77.
10. Johnston CL, Cox HC, Gomm JJ, Coombes RC. Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. J Biol Chem 1995;270:30643-50.
11. Tan SH, Nevalainen MT. Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr Relat Cancer 2008;15:367-90. (Pubitemid 351880829)
12. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88. (Pubitemid 30339203)
13. Vafaizadeh V, Klemmt P, Brendel C, Weber K, Doebele C, Britt K, et al. Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells 2010;28:928-38.
14. Richer JK, Lange CA, Manning NG, Owen G, Powell R, Horwitz KB. Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem 1998;273:31317-26. (Pubitemid 28533148)
15. Subtil-Rodriguez A, Millan-Arino L, Quiles I, Ballare C, Beato M, Jordan A. Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking. Mol Cell Biol 2008;28:3830-49. (Pubitemid 351732916)
16. Santos SJ, Haslam SZ, Conrad SE. Signal transducer and activator of transcription 5a mediates mammary ductal branching and proliferation in the nulliparous mouse. Endocrinology 2010;151:2876-85.
17. Humphreys RC, Lydon JP, O'Malley BW, Rosen JM. Use of PRKO mice to study the role of progesterone in mammary gland development. J Mammary Gland Biol Neoplasia 1997;2:343-54. (Pubitemid 127718719)
18. Lamb C, Simian M, Molinolo A, Pazos P, Lanari C. Regulation of cell growth of a progestin-dependent murine mammary carcinoma in vitro: progesterone receptor involvement in serum or growth factor-induced cell proliferation. J Steroid Biochem Mol Biol 1999;70:133-42. (Pubitemid 29528423)
19. Gardmo C, Kotokorpi P, Helander H, Mode A. Transfection of adult primary rat hepatocytes in culture. Biochem Pharmacol 2005;69:1805-13. (Pubitemid 40780080)
20. Helguero LA, Viegas M, Asaithamby A, Shyamala G, Lanari C, Molinolo AA. Progesterone receptor expression in medroxyprogesterone acetate-induced murine mammary carcinomas and response to endocrine treatment. Breast Cancer Res Treat 2003;79:379-90. (Pubitemid 36750945)
21. Afhuppe W, Beekman JM, Otto C, Korr D, Hoffmann J, Fuhrmann U, et al. In vitro characterization of ZK 230211-a type III progesterone receptor antagonist with enhanced antiproliferative properties. J Steroid Biochem Mol Biol 2010;119:45-55.
22. Clevenger CV. Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 2004;165:1449-60. (Pubitemid 39435145)
23. Sabbieti MG, Marchetti L, Gabrielli MG, Menghi M, Materazzi S, Menghi G, et al. Prostaglandins differently regulate FGF-2 and FGF receptor expression and induce nuclear translocation in osteoblasts via MAPK kinase. Cell Tissue Res 2005;319:267-78. (Pubitemid 40174520)
24. Behrens C, Lin HY, Lee JJ, Raso MG, Hong WK, Wistuba II, et al. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res 2008;14:6014-22.
25. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996;271:15292-7. (Pubitemid 26195013)
26. Santos SJ, Haslam SZ, Conrad SE. Estrogen and progesterone are critical regulators of Stat5a expression in the mouse mammary gland. Endocrinology 2008;149:329-38.
27. Yamashita H, Nishio M, Fujii Y, Iwase H. Dominant-negative Stat5 inhibits growth and induces apoptosis in T47D-derived tumors in nude mice. Cancer Sci 2004;95:662-5. (Pubitemid 39255814)
28. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998;93:841-50.
29. Moore MR, Zhou JL, Blankenship KA, Strobl JS, Edwards DP, Gentry RN. A sequence in the 5' flanking region confers progestin responsiveness on the human c-myc gene. J Steroid Biochem Mol Biol 1997;62:243-52. (Pubitemid 27504755)
30. Moore MR, Conover JL, Franks KM. Progestin effects on long-term growth, death, and Bcl-xL in breast cancer cells. Biochem Biophys Res Commun 2000;277:650-4.
31. Lockwood CJ, Murk W, Kayisli UA, Buchwalder LF, Huang ST, Funai EF, et al. Progestin and thrombin regulate tissue factor expression in human term decidual cells. J Clin Endocrinol Metab 2009;94:2164-70.
32. Liang Y, Besch-Williford C, Brekken RA, Hyder SM. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res 2007;67:9929-36. (Pubitemid 47621242)
33. Clemm DL, Sherman L, Boonyaratanakornkit V, Schrader WT, Weigel NL, Edwards DP. Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol Endocrinol 2000;14:52-65. (Pubitemid 32260327)
34. Hynes NE, Dey JH. Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Res 2010;70:5199-202.
35. Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010;70:4151-62.
36. Murakami M, Elfenbein A, Simons M. Noncanonical fibroblast growth factor signalling in angiogenesis. Cardiovasc Res 2008;78:223-31. (Pubitemid 351556091)
37. Schwertfeger KL. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets 2009;10:632-44.
38. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116-29.
39. Dressing GE, Hagan CR, Knutson TP, Daniel AR, Lange CA. Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocr Relat Cancer 2009;16:351-61.
40. Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA. Mitogen activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol 2003;17:628-42. (Pubitemid 36403575)
41. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, et al. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 2001;8:269-80. (Pubitemid 32831545)
42. Proietti C, Salatino M, Rosemblit C, Carnevale R, Pecci A, Kornblihtt AR, et al. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol 2005;25:4826-40. (Pubitemid 40781085)
43. Mote PA, Johnston JF, Manninen T, Tuohimaa P, Clarke CL. Detection of progesterone receptor forms A and B by immunohistochemical analysis. J Clin Pathol 2001;54:624-30. (Pubitemid 32756446)
44. Stoecklin E, Wissler M, Moriggl R, Groner B. Specific DNA binding of Stat5, but not of glucocorticoid receptor, is required for their functional cooperation in the regulation of gene transcription. Mol Cell Biol 1997;17:6708-16. (Pubitemid 27451218)
45. Quiles I, Millan-Arino L, Subtil-Rodriguez A, Minana B, Spinedi N, Ballare C, et al. Mutational analysis of progesterone receptor functional domains in stable cell lines delineates sets of genes regulated by different mechanisms. Mol Endocrinol 2009;23:809-26.
46. Pardo OE, Latigo J, Jeffery RE, Nye E, Poulsom R, Spencer-Dene B, et al. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 2009;69:8645-51.
47. Wierstra I, Alves J. The c-myc promoter: still MysterY and challenge. Adv Cancer Res 2008;99:113-333. (Pubitemid 350137254)
48. Robertson SC, Meyer AN, Hart KC, Galvin BD, Webster MK, Donoghue DJ. Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain. Proc Natl Acad Sci U S A 1998;95:4567-72. (Pubitemid 28207953)
49. Ogawa S, Satake M, Ikuta K. Physical and functional interactions between STAT5 and Runx transcription factors. J Biochem 2008;143:695-709. (Pubitemid 351670658)
50. Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 2004;22:2053-60. (Pubitemid 41095137)